Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Authors

• William Kelly

Publication/Presentation Date

10-2023

Volume

34

Issue

2

First Page

953

Last Page

954

Published In/Presented At

https://doi.org/10.1016/j.annonc.2023.09.2715

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article